FDA Approves SAXENDA — Novo Nordisk Pharmaceutical Industries, LP

Novo Nordisk Pharmaceutical Industries, LP received FDA approval for Saxenda (liraglutide) in 2014, a GLP-1 agonist that entered the market to address the growing demand for clinically proven weight management solutions. The approval positioned Saxenda as a pivotal competitor to existing anti-obesity therapies, paving the way for Novo Nordisk to capitalize on the expanding market for long-term weight-loss treatments.